TGTX - TG Therapeutics, Inc.
| Previous Close | 4.6500 |
| Open | 4.6800 |
| Bid | 4.04 x 3000 |
| Ask | 5.00 x 1000 |
| Day's Range | 4.5900 - 4.7700 |
| 52 Week Range | 3.3200 - 17.3500 |
| Volume | 1,110,336 |
| Avg. Volume | 1,284,911 |
| Market Cap | 366.466M |
| Beta (3Y Monthly) | 1.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.08 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.83 |
- GlobeNewswire•2 days ago
TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting
TG Therapeutics, Inc. (TGTX), today announced that the final Phase 2 data from the multicenter trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS) has been selected for presentation at the upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) annual meeting, to be held February 28 through March 2, 2019 in Dallas, Texas. This data was previously presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting held in October of 2018. Highlights from the abstract and details of the poster presentation are outlined below.
- Zacks•4 days ago
Key Factors to Know Ahead of TransEnterix (TRXC) Q4 Earnings
TransEnterix (TRXC) is anticipated to witness robust top-line growth in Q4 on the back of multiple product developments.
- Zacks•6 days ago
HMS Holdings (HMSY) to Report Q4 Earnings: What's in Store?
HMS Holdings (HMSY) expects to gain from its total population management or TPM business in fourth-quarter 2018.
- Zacks•9 days ago
Key Factors Likely to Shape CVS Health's (CVS) Q4 Earnings
CVS Health (CVS) expects drug price inflation, product launches and higher utilization to fuel growth in Q4.
- Zacks•13 days ago
Can M&A Activity Drive Quest Diagnostics (DGX) Q4 Earnings?
Quest Diagnostics' (DGX) increasing partnerships with other health care leaders and strategic acquisitions are promising abundant opportunities for the company's top and bottom-line improvement.
- Zacks•25 days ago
TG Therapeutics (TGTX) Upgraded to Buy: Here's What You Should Know
TG Therapeutics (TGTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire•25 days ago
TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase I Triple Therapy Combination Trial of Ublituximab, Umbralisib, and Ibrutinib in The Lancet Haematology
TG Therapeutics, Inc. (TGTX) today announced the publication of results from the multicenter Phase 1 triple combination trial of ublituximab (TG-1101), the Company’s anti-CD20 monoclonal antibody, umbralisib (TGR-1202), the Company’s oral once-daily PI3K delta inhibitor, and ibrutinib, the oral Bruton's tyrosine kinase (BTK) inhibitor, in The Lancet Haematology. The paper includes safety and efficacy information from patients with relapsed or refractory B-cell malignancies, including 23 patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and 23 patients with non-Hodgkin lymphoma (NHL).
- Zacks•27 days ago
Has TG Therapeutics (TGTX) Outpaced Other Medical Stocks This Year?
Is (TGTX) Outperforming Other Medical Stocks This Year?
- Simply Wall St.•last month
Do Insiders Own Shares In TG Therapeutics, Inc. (NASDAQ:TGTX)?
The big shareholder groups in TG Therapeutics, Inc. (NASDAQ:TGTX) have power over the company. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their Read More...
- GlobeNewswire•last month
TG Therapeutics Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Umbralisib for the Treatment of Marginal Zone Lymphoma
TG Therapeutics, Inc. (TGTX), a biopharmaceutical company dedicated to developing medicines for patients with B-cell mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for umbralisib (TGR-1202) for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 regimen. There are currently no fully approved agents for MZL.
- Zacks•last month
Canopy Growth (CGC) in Focus: Stock Moves 11.1% Higher
Canopy Growth (CGC) shares rose more than 11% in the last trading session, amid huge volumes.
- Thomson Reuters StreetEvents•last month
Edited Transcript of TGTX earnings conference call or presentation 7-Aug-18 8:30pm GMT
Q2 2018 TG Therapeutics Inc Earnings Call
- GlobeNewswire•2 months ago
TG Therapeutics, Inc. to Present at the 37th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 07, 2019 -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will.
- GlobeNewswire•2 months ago
Market Trends Toward New Normal in Brunswick, Atkore International Group, TG Therapeutics, Las Vegas Sands, Benchmark Electronics, and ProPetro Holding — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Jan. 07, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Investopedia•2 months ago
The Most Promising Biotech Names Heading Into 2019
Historically, biotech companies have offered investors the possibility of outsized success, but they also carry high levels of risk. The reason for this is that biotech companies traditionally race to develop cutting edge products. When a product in a biotech company's pipeline fails to materialize or to produce the desired results, that company's stock price can suffer the consequences.
- GlobeNewswire•2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (“TG” or the “Company”) (TGTX) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether TG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
- GlobeNewswire•2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Therapeutics, Inc. - TGTX
Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. (“TG” or the “Company”) (TGTX). Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether TG and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
- Zacks•2 months ago
5 Beaten-Down Medical Product Stocks to Rebound in 2019
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.
- Insider Monkey•2 months ago
Hedge Funds Are Buying TG Therapeutics Inc (TGTX)
“Value has performed relatively poorly since the 2017 shift, but we believe challenges to the S&P 500’s dominance are mounting and resulting active opportunities away from the index are growing. At some point, this fault line will break, likely on the back of rising rates, and all investors will be reminded that the best time […]
- GlobeNewswire•2 months ago
TG Therapeutics, Inc. and Dana-Farber Cancer Institute Announce Publication of Clinical Data from the Phase 1/1b Trial of Umbralisib in Combination with Ibrutinib in Lancet Haematology
TG Therapeutics, Inc. (TGTX) and Dana-Farber Cancer Institute today announced the publication of results from the multicenter Phase 1/1b trial of umbralisib (TGR-1202), TG Therapeutics’ novel once-daily PI3K delta inhibitor, in combination with ibrutinib, the oral Bruton's tyrosine kinase (BTK) inhibitor, in Lancet Haematology. This investigator-initiated trial was conducted at Dana-Farber Cancer Institute and four additional academic and community sites across the USA in collaboration with the Leukemia and Lymphoma Society Blood Cancer Research Partnership with funding by TG Therapeutics.
